| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | 0.056 | 0.1 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | -0.053 | 0.1 |
| mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | -0.048 | 0.1 |
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | -0.052 | 0.1 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.1 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | 0.056 | 0.1 |
| mRNA | UNC0321 | CTRPv2 | pan-cancer | AAC | 0.056 | 0.1 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.1 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.046 | 0.1 |